KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Capital Expenditures (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Capital Expenditures for 17 consecutive years, with $40.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 108.51% year-over-year to $40.7 million, compared with a TTM value of $103.0 million through Dec 2025, up 20.62%, and an annual FY2025 reading of $103.0 million, up 20.62% over the prior year.
  • Capital Expenditures was $40.7 million for Q4 2025 at Biomarin Pharmaceutical, up from $28.4 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $40.7 million in Q4 2025 and bottomed at $16.8 million in Q1 2025.
  • Average Capital Expenditures over 5 years is $25.1 million, with a median of $25.0 million recorded in 2021.
  • The sharpest move saw Capital Expenditures tumbled 37.1% in 2021, then soared 108.51% in 2025.
  • Year by year, Capital Expenditures stood at $28.7 million in 2021, then increased by 24.18% to $35.7 million in 2022, then fell by 18.97% to $28.9 million in 2023, then tumbled by 32.46% to $19.5 million in 2024, then skyrocketed by 108.51% to $40.7 million in 2025.
  • Business Quant data shows Capital Expenditures for BMRN at $40.7 million in Q4 2025, $28.4 million in Q3 2025, and $17.1 million in Q2 2025.